Information Provided By: 
Fly News Breaks for February 20, 2018
SRPT, SLDB
Feb 20, 2018 | 06:48 EDT
JPMorgan analyst Anupam Rama started Solid Biosciences (SLDB) with a Neutral rating and $28 price target. The analyst highlights Solid's failure to disclose a manufacturing-related partial clinical hold on its recently initiated Phase 1 trial during the initial public offering process as well as a recent academic paper that calls into question the safety of high-dose viral vectors. He adds that competitor Sarepta (SRPT) will be first with clinical data in the micro-dystrophin space.
News For SLDB;SRPT From the Last 2 Days
There are no results for your query SLDB;SRPT
